Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion.

[1]  E. Parkes,et al.  cGAS–STING signalling in cancer: striking a balance with chromosomal instability , 2023, Biochemical Society transactions.

[2]  O. Boyman,et al.  A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases , 2022, medRxiv.

[3]  W. Schief,et al.  IL-2 secreting T helper cells promote EF B cell maturation via intrinsic regulation of B cell mTOR/AKT/Blimp-1 axis , 2022, bioRxiv.

[4]  T. Malek,et al.  Engineering IL-2 for immunotherapy of autoimmunity and cancer , 2022, Nature Reviews Immunology.

[5]  R. Kimple,et al.  Biology of HPV Mediated Carcinogenesis and Tumor Progression. , 2021, Seminars in radiation oncology.

[6]  W. Gu,et al.  Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives , 2021, Molecular therapy oncolytics.

[7]  P. Kaminski,et al.  Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases , 2021, Cells.

[8]  María Teresa Corona-Ortega,et al.  Evidence that the viral oncoproteins E6 and E7 of HPV induce the expression of a functional IL-2R on cervical cancer cells. , 2021, Cytokine.

[9]  Sunil Kumar Singh,et al.  Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. , 2021, Drug discovery today.

[10]  A. Akarca,et al.  CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity , 2020, Nature Cancer.

[11]  Yi Yuan,et al.  HPV post-infection microenvironment and cervical cancer. , 2020, Cancer letters.

[12]  Adriana Gutiérrez-Hoya,et al.  Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins , 2020, Cells.

[13]  O. Boyman,et al.  Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity , 2020, Science Translational Medicine.

[14]  J. Christensen,et al.  Cytotoxic CD8+ T cells in cancer and cancer immunotherapy , 2020, British Journal of Cancer.

[15]  K. Simpson,et al.  Loss of HPV type 16 E7 restores cGAS-STING responses in human papilloma virus-positive oropharyngeal squamous cell carcinomas cells. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[16]  S. K. Campos,et al.  Vesicular trafficking permits evasion of cGAS/STING surveillance during initial human papillomavirus infection , 2020, bioRxiv.

[17]  J. Califano,et al.  B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade , 2020, Clinical Cancer Research.

[18]  A. Pescatore,et al.  Life, death, and autophagy in cancer: NF-κB turns up everywhere , 2020, Cell Death & Disease.

[19]  Yi Liu,et al.  Research Progress on Tumor-Associated Macrophages and Inflammation in Cervical Cancer , 2020, BioMed research international.

[20]  Hua Liang,et al.  Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis. , 2020, Cancer letters.

[21]  S. Bakhoum,et al.  The Cytosolic DNA-Sensing cGAS-STING Pathway in Cancer. , 2019, Cancer discovery.

[22]  Jingnan Wang,et al.  The prognostic landscape of tumor-infiltrating immune cells in cervical cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  J. Hiscott,et al.  Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes , 2019, Journal of Virology.

[24]  Xu Wang,et al.  Human Papillomavirus 16 E6 and E7 Synergistically Repress Innate Immune Gene Transcription , 2019, mSphere.

[25]  G. Kroemer,et al.  Effects of interleukin-2 in immunostimulation and immunosuppression , 2019, The Journal of experimental medicine.

[26]  Cierra S. Hong,et al.  Neutrophils promote tumor resistance to radiation therapy , 2019, Proceedings of the National Academy of Sciences.

[27]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[28]  A. Aguilar-Lemarroy,et al.  E6/E7 and E6* From HPV16 and HPV18 Upregulate IL-6 Expression Independently of p53 in Keratinocytes , 2019, Front. Immunol..

[29]  U. Jeschke,et al.  The Formation and Therapeutic Update of Tumor-Associated Macrophages in Cervical Cancer , 2019, International journal of molecular sciences.

[30]  Yan-Mei Zhang,et al.  Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment , 2019, Cell Death & Disease.

[31]  N. Pang,et al.  Role of Regulatory B Cells in the Progression of Cervical Cancer , 2019, Mediators of inflammation.

[32]  L. Virág,et al.  Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos , 2019, Redox biology.

[33]  E. Baracat,et al.  Lactate secreted by cervical cancer cells modulates macrophage phenotype , 2019, Journal of leukocyte biology.

[34]  Jorgelina Barrios De Tomasi,et al.  Immunity in the Cervix: Interphase between Immune and Cervical Epithelial Cells , 2019, Journal of immunology research.

[35]  A. Poggi,et al.  Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects , 2019, Cancers.

[36]  A. Regev,et al.  Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers , 2019, Proceedings of the National Academy of Sciences.

[37]  R. Bohle,et al.  Cervical Cancer-Instructed Stromal Fibroblasts Enhance IL23 Expression in Dendritic Cells to Support Expansion of Th17 Cells. , 2019, Cancer research.

[38]  V. Kalia,et al.  Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2—A Balancing Act , 2018, Front. Immunol..

[39]  K. Zeng,et al.  The role of regulatory T cells in pathogenesis and therapy of human papillomavirus-related diseases, especially in cancer. , 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[40]  Z. Gu,et al.  Correlative analysis of the expression of IL-10 and Ki-67 in human cervical cancer and cervical intraepithelial neoplasias and human papillomavirus infection , 2018, Oncology letters.

[41]  R. Cobucci,et al.  Th17 response in patients with cervical cancer , 2018, Oncology letters.

[42]  J. Pollard,et al.  Diverse Functions of Macrophages in Different Tumor Microenvironments. , 2018, Cancer research.

[43]  E. Crivellato,et al.  Cross talk between natural killer cells and mast cells in tumor angiogenesis , 2018, Inflammation Research.

[44]  W. Leonard,et al.  Biology and regulation of IL-2: from molecular mechanisms to human therapy , 2018, Nature Reviews Immunology.

[45]  K. Leon,et al.  Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells , 2018, The Journal of Immunology.

[46]  T. Abe,et al.  Revisiting the role of IRF3 in inflammation and immunity by conditional and specifically targeted gene ablation in mice , 2018, Proceedings of the National Academy of Sciences.

[47]  Asmita Das,et al.  IL-2 mediates NK cell proliferation but not hyperactivity , 2018, Immunologic research.

[48]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[49]  Cheng Chen,et al.  Effects of Th17 cells and IL‐17 in the progression of cervical carcinogenesis with high‐risk human papillomavirus infection , 2017, Cancer medicine.

[50]  J. Garssen,et al.  Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. , 2017, Cellular immunology.

[51]  A. McKenzie,et al.  TH2 cell development and function , 2017, Nature Reviews Immunology.

[52]  L. Liang,et al.  Clinical Significance of CD163+ and CD68+ Tumor-associated Macrophages in High-risk HPV-related Cervical Cancer , 2017, Journal of Cancer.

[53]  D. Beebe,et al.  Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen , 2017, Proceedings of the National Academy of Sciences.

[54]  Wei Zhu,et al.  Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer , 2017, World Journal of Surgical Oncology.

[55]  G. Lal,et al.  The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy , 2017, Front. Immunol..

[56]  J. Barrett,et al.  Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection , 2017, Viruses.

[57]  A. Longatto-Filho,et al.  Local and systemic immunomodulatory mechanisms triggered by Human Papillomavirus transformed cells: a potential role for G-CSF and neutrophils , 2017, Scientific Reports.

[58]  F. Hoppe-Seyler,et al.  The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. , 2017, Trends in microbiology.

[59]  P. Lambert,et al.  Human Papillomavirus and the Stroma: Bidirectional Crosstalk during the Virus Life Cycle and Carcinogenesis , 2017, Viruses.

[60]  J. Madrigal,et al.  B cell regulation in cancer and anti-tumor immunity , 2017, Cellular &Molecular Immunology.

[61]  D. Raben,et al.  High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes , 2017, Scientific Reports.

[62]  K. P. Trugilo,et al.  The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. , 2017, Cytokine & growth factor reviews.

[63]  L. Banks,et al.  Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. , 2017, Mutation research. Reviews in mutation research.

[64]  P. Greenberg,et al.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. , 2017, Cancer cell.

[65]  C. Klein,et al.  Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines , 2017, Oncoimmunology.

[66]  K. Oh,et al.  IL2 is required for functional maturation of regulatory T cells , 2017, Animal cells and systems.

[67]  B. Ruffell,et al.  Dendritic Cells and Cancer Immunity. , 2016, Trends in immunology.

[68]  B. Brannetti,et al.  Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2 , 2016, Science Translational Medicine.

[69]  Cheng-ming Sun,et al.  B cells promote tumor progression in a mouse model of HPV‐mediated cervical cancer , 2016, International journal of cancer.

[70]  Jingping Yuan,et al.  Co-evolution of tumor-associated macrophages and tumor neo-vessels during cervical cancer invasion , 2016, Oncology letters.

[71]  A. Rudensky,et al.  An essential role for IL-2 receptor in regulatory T cell function , 2016, Nature Immunology.

[72]  P. Lambert,et al.  Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14 , 2016, mBio.

[73]  G. Shurin,et al.  Tumor-derived factors modulating dendritic cell function , 2016, Cancer Immunology, Immunotherapy.

[74]  P. Duerksen-Hughes,et al.  Chronic oxidative stress increases the integration frequency of foreign DNA and human papillomavirus 16 in human keratinocytes. , 2016, American journal of cancer research.

[75]  E. Felip,et al.  TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. , 2016, The Lancet. Oncology.

[76]  M. Addepalli,et al.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.

[77]  S. Kaech,et al.  The multifaceted role of CD4+ T cells in CD8+ T cell memory , 2016, Nature Reviews Immunology.

[78]  Geetha Chalasani,et al.  B Cells, Antibodies, and More. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[79]  R. Bohle,et al.  Stromal Fibroblasts Induce CCL20 through IL6/C/EBPβ to Support the Recruitment of Th17 Cells during Cervical Cancer Progression. , 2015, Cancer research.

[80]  Elizabeth E Gray,et al.  DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway , 2015, Science.

[81]  M. Xue,et al.  Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells. , 2015, Genetics and molecular research : GMR.

[82]  E. Martinelli,et al.  Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer , 2015, PloS one.

[83]  J. Galon,et al.  From mice to humans: developments in cancer immunoediting. , 2015, The Journal of clinical investigation.

[84]  Wen‐Chun Chang,et al.  Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma , 2015, International Journal of Gynecologic Cancer.

[85]  P. Delvenne,et al.  HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells , 2015, International journal of cancer.

[86]  W. Klapper,et al.  Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. , 2015, Leukemia research.

[87]  Florian Klemm,et al.  Microenvironmental regulation of therapeutic response in cancer. , 2015, Trends in cell biology.

[88]  P. Delvenne,et al.  Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion , 2015, Oncoimmunology.

[89]  S. H. van der Burg,et al.  The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation , 2015, Nature Communications.

[90]  Yan He,et al.  Preferential Recruitment of Th17 Cells to Cervical Cancer via CCR6-CCL20 Pathway , 2015, PloS one.

[91]  E. Jordanova,et al.  Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer , 2015, Oncoimmunology.

[92]  Yongge Zhao,et al.  Interleukin‐2‐mediated inhibition of dendritic cell development correlates with decreased CD135 expression and increased monocyte/macrophage precursors , 2014, Immunology.

[93]  Jun Zhou,et al.  Tumor‐associated macrophages induce lymphangiogenesis in cervical cancer via interaction with tumor cells , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[94]  A. Burguete-García,et al.  Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. , 2014, World journal of clinical oncology.

[95]  D. Noonan,et al.  A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis , 2014, Journal of the National Cancer Institute.

[96]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[97]  Takashi Takahashi,et al.  Tumor-Derived Interleukin-1 Promotes Lymphangiogenesis and Lymph Node Metastasis through M2-Type Macrophages , 2014, PloS one.

[98]  S. Smola,et al.  Cervical cancer cell‐derived interleukin‐6 impairs CCR7‐dependent migration of MMP‐9‐expressing dendritic cells , 2014, International journal of cancer.

[99]  L. Rocha-Zavaleta,et al.  IL-2 Enhances Cervical Cancer Cells Proliferation and JAK3/STAT5 Phosphorylation at Low Doses, While at High Doses IL-2 Has Opposite Effects , 2014, Cancer investigation.

[100]  Deborah M. Brown,et al.  Inflammation Enhances IL-2 Driven Differentiation of Cytolytic CD4 T Cells , 2014, PloS one.

[101]  M. Wittmann,et al.  Human Papillomavirus E7 Oncoprotein Increases Production of the Anti-Inflammatory Interleukin-18 Binding Protein in Keratinocytes , 2014, Journal of Virology.

[102]  T. Mayadas,et al.  The multifaceted functions of neutrophils. , 2014, Annual review of pathology.

[103]  G. Berchem,et al.  The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity , 2013, Front. Immunol..

[104]  I. Mellman.  Dendritic Cells: Master Regulators of the Immune Response , 2013, Cancer Immunology Research.

[105]  K. Dimopoulos,et al.  HPV Infection: Immunological Aspects and Their Utility in Future Therapy , 2013, Infectious diseases in obstetrics and gynecology.

[106]  Hong-wei Wang,et al.  Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia , 2013, Immunology.

[107]  G. Trinchieri,et al.  The Human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter , 2013, The Journal of experimental medicine.

[108]  Ana R. Pacios,et al.  Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 , 2013, The Journal of Immunology.

[109]  A. Rudensky,et al.  IL-2–dependent adaptive control of NK cell homeostasis , 2013, The Journal of experimental medicine.

[110]  S. H. van der Burg,et al.  Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response , 2013, PLoS pathogens.

[111]  D. Isenberg,et al.  CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation , 2013, Science Translational Medicine.

[112]  W. Leonard,et al.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. , 2013, Immunity.

[113]  T. Hagemann,et al.  The tumor microenvironment at a glance , 2012, Journal of Cell Science.

[114]  Hideo Negishi,et al.  The IRF family of transcription factors , 2012, Oncoimmunology.

[115]  E. Murta,et al.  Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. , 2012, Human immunology.

[116]  O. Mandelboim,et al.  Virus-mediated inhibition of natural cytotoxicity receptor recognition , 2012, Cellular and Molecular Life Sciences.

[117]  S. Albelda,et al.  Tumor-associated neutrophils: friend or foe? , 2012, Carcinogenesis.

[118]  A. Zychlinsky,et al.  Neutrophil function: from mechanisms to disease. , 2012, Annual review of immunology.

[119]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[120]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[121]  B. Xia,et al.  CD4+T Cells: Differentiation and Functions , 2012, Clinical & developmental immunology.

[122]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[123]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[124]  Helen H. W. Chen,et al.  Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[125]  E. Murta,et al.  Clinical Medicine Insights: Oncology Circulating Cytokines and Nitric Oxide Are Involved in the Inhibition of Neutrophil Migration in Patients with Uterine Cervical Neoplasia , 2022 .

[126]  D. Kuang,et al.  Neutrophils promote motility of cancer cells via a hyaluronan‐mediated TLR4/PI3K activation loop , 2011, The Journal of pathology.

[127]  Ming-Yih Wu,et al.  Tumor-infiltrating lymphocytes contain a higher proportion of FOXP3(+) T lymphocytes in cervical cancer. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.

[128]  Yan-mei Yang,et al.  COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. , 2011, Microvascular research.

[129]  T. Iftner,et al.  High-Risk Human Papillomaviruses Repress Constitutive Kappa Interferon Transcription via E6 To Prevent Pathogen Recognition Receptor and Antiviral-Gene Expression , 2011, Journal of Virology.

[130]  S. H. van der Burg,et al.  M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells , 2011, The Journal of Immunology.

[131]  L. Coussens,et al.  B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis , 2011, Proceedings of the National Academy of Sciences.

[132]  G. Hill,et al.  CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis , 2011, Proceedings of the National Academy of Sciences.

[133]  W. Leonard,et al.  Cytokine receptor modulation by interleukin-2 broadly regulates T helper cell lineage differentiation , 2011, Nature immunology.

[134]  S. H. van der Burg,et al.  Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes , 2011, PloS one.

[135]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[136]  J. Cáceres-Cortés,et al.  Cationic liposomes bearing IL-2 on their external surface induced mice leukocytes to kill human cervical cancer cells in vitro, and significantly reduced tumor burden in immunodepressed mice , 2011, Journal of drug targeting.

[137]  A. Abbas,et al.  Cutting Edge: Mechanisms of IL-2–Dependent Maintenance of Functional Regulatory T Cells , 2010, The Journal of Immunology.

[138]  Hongwei Chen,et al.  A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix , 2010, Cellular and Molecular Immunology.

[139]  S. Batra,et al.  Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection , 2010, Molecular Cancer.

[140]  T. Malek,et al.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity. , 2010, Immunity.

[141]  L. Villa,et al.  Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth , 2010, BMC Immunology.

[142]  B. Weiss-Steider,et al.  Evidence that cervical cancer cells secrete IL-2, which becomes an autocrine growth factor. , 2010, Cytokine.

[143]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[144]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[145]  M. Bevan,et al.  Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. , 2010, Immunity.

[146]  Dorothea Busse,et al.  Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments , 2010, Proceedings of the National Academy of Sciences.

[147]  B. Weiss-Steider,et al.  Characterization of cationic liposomes having IL-2 expressed on their external surface, and their affinity to cervical cancer cells expressing the IL-2 receptor , 2009, Journal of drug targeting.

[148]  K. R. Daghastanli,et al.  HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses , 2009, Clinical Cancer Research.

[149]  A. Daneri-Navarro,et al.  Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions , 2009, BMC Cancer.

[150]  M. Delgado,et al.  Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix. , 2008, Investigacion clinica.

[151]  L. Fouser,et al.  Th17 cytokines and their emerging roles in inflammation and autoimmunity , 2008, Immunological reviews.

[152]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[153]  E. Tartour,et al.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  T. Lebien,et al.  B lymphocytes: how they develop and function. , 2008, Blood.

[155]  M. Caligiuri,et al.  Human natural killer cells. , 2008, Blood.

[156]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[157]  G. Mukherjee,et al.  ORIGINAL ARTICLE: Regulatory T Cells in a Spectrum of HPV‐Induced Cervical Lesions: Cervicitis, Cervical Intraepithelial Neoplasia and Squamous Cell Carcinoma , 2008, American journal of reproductive immunology.

[158]  L. Kaiser,et al.  B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models , 2008, Journal of immunotherapy.

[159]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[160]  M. Deng,et al.  Tumor‐derived tumor necrosis factor‐alpha promotes progression and epithelial‐mesenchymal transition in renal cell carcinoma cells , 2008, Cancer science.

[161]  Chen Dong,et al.  TH17 cells in development: an updated view of their molecular identity and genetic programming , 2008, Nature Reviews Immunology.

[162]  Lewis L Lanier,et al.  Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.

[163]  S. H. van der Burg,et al.  Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients? , 2008, Clinical Cancer Research.

[164]  G. Cook,et al.  High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells , 2008, Oncogene.

[165]  X. Zhang,et al.  Macrophage activation by endogenous danger signals , 2008, The Journal of pathology.

[166]  J. Dayer,et al.  The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors , 2007, Arthritis research & therapy.

[167]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[168]  M. Stanley,et al.  HPV: from infection to cancer. , 2007, Biochemical Society transactions.

[169]  T. Kiyono,et al.  Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins , 2007, Cancer science.

[170]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[171]  N. Coleman,et al.  Integration of high‐risk human papillomavirus: a key event in cervical carcinogenesis? , 2007, The Journal of pathology.

[172]  M. Zabel,et al.  Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. , 2007, Folia morphologica.

[173]  J. DiGiovanni,et al.  Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis , 2007, Molecular carcinogenesis.

[174]  J. M. van der Hulst,et al.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens , 2007, Proceedings of the National Academy of Sciences.

[175]  T. Shima,et al.  Expression of indoleamine 2, 3‐dioxygenase and the recruitment of Foxp3‐expressing regulatory T cells in the development and progression of uterine cervical cancer , 2007, Cancer science.

[176]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[177]  J. Lin,et al.  Stat3 activation in human endometrial and cervical cancers , 2007, British Journal of Cancer.

[178]  S. Ju,et al.  Cutting Edge: A Regulatory T Cell-Dependent Novel Function of CD25 (IL-2Rα) Controlling Memory CD8+ T Cell Homeostasis1 , 2007, The Journal of Immunology.

[179]  A. Sica,et al.  New vistas on macrophage differentiation and activation , 2007, European journal of immunology.

[180]  M. Farrar,et al.  IL-2 Receptor β-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells1 , 2007, The Journal of Immunology.

[181]  D. Tamang,et al.  Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. , 2006, Cytokine.

[182]  Veeresh Gadag,et al.  Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. , 2006, International immunology.

[183]  A. Teschendorff,et al.  Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. , 2006, Carcinogenesis.

[184]  Jean Imbert,et al.  Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. , 2006, Cytokine & growth factor reviews.

[185]  A. Malpica,et al.  Deficiencies in myeloid antigen‐presenting cells in women with cervical squamous intraepithelial lesions , 2006, Cancer.

[186]  B. Vargaftig,et al.  Systemic administration of interleukin‐2 inhibits inflammatory neutrophil migration: role of nitric oxide , 2006, British journal of pharmacology.

[187]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[188]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[189]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[190]  R. Rees,et al.  The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines , 2006, Cancer Immunology, Immunotherapy.

[191]  M. Stanley,et al.  Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[192]  Shizuo Akira,et al.  Innate immune recognition of viral infection , 2006, Nature Immunology.

[193]  S. Ullrich,et al.  High‐risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract , 2006, Immunology.

[194]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[195]  F. Cunha,et al.  Circulating neutrophils may play a role in the host response in cervical cancer , 2006, International Journal of Gynecologic Cancer.

[196]  K. Garcia,et al.  Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γc Receptors , 2005, Science.

[197]  L. Glimcher,et al.  IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508 , 2005, The Journal of experimental medicine.

[198]  R. Catarino,et al.  G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancer , 2005 .

[199]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[200]  K. Arihiro,et al.  Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. , 2005, Oncology reports.

[201]  S. Gaffen,et al.  Overview of interleukin-2 function, production and clinical applications. , 2004, Cytokine.

[202]  L. Rocha-Zavaleta,et al.  Interleukin-2 (IL-2) receptor-betagamma signalling is activated by c-Kit in the absence of IL-2, or by exogenous IL-2 via JAK3/STAT5 in human papillomavirus-associated cervical cancer. , 2004, Cellular signalling.

[203]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[204]  D. Donner,et al.  Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors , 2004, Oncogene.

[205]  B. Nelson.  IL-2, Regulatory T Cells, and Tolerance , 2004, The Journal of Immunology.

[206]  W. Paul,et al.  Interleukin 2 plays a central role in Th2 differentiation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[207]  M. Ricote,et al.  Interleukin-2 and its receptor complex (α, β and γ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study , 2003, Breast Cancer Research.

[208]  K. Alexander,et al.  RNA Interference of Human Papillomavirus Type 18 E6 and E7 Induces Senescence in HeLa Cells , 2003, Journal of Virology.

[209]  Chia-Hung Chou,et al.  Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway , 2003, Oncogene.

[210]  Tom Freeman,et al.  Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. , 2002, Cancer research.

[211]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[212]  C. Woodworth.  HPV innate immunity. , 2002, Frontiers in bioscience : a journal and virtual library.

[213]  T. Malek,et al.  CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. , 2002, Immunity.

[214]  I. Arany,et al.  Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5'-segment of the upstream regulatory region (URR). , 2002, Antiviral research.

[215]  S. Um,et al.  Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. , 2002, Cancer letters.

[216]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[217]  M. Kuo,et al.  The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway , 2001, Oncogene.

[218]  B. Sheu,et al.  Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer1 , 2001, The Journal of Immunology.

[219]  G. Matlashewski,et al.  Control of interferon signaling in human papillomavirus infection. , 2001, Cytokine & growth factor reviews.

[220]  C. Woodworth,et al.  Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF-κB-Responsive Genes in Cervical Keratinocytes , 2001, Journal of Virology.

[221]  S. Gaffen.  Signaling domains of the interleukin 2 receptor. , 2001, Cytokine.

[222]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[223]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[224]  P. Magnusson,et al.  Cervical cancer risk: is there a genetic component? , 2000, Molecular medicine today.

[225]  J. Bertoglio,et al.  Association of STAT1, STAT3 and STAT5 proteins with the IL‐2 receptor involves different subdomains of the IL‐2 receptor β chain , 2000, European journal of immunology.

[226]  F. Bethencourt,et al.  IL-2, Its Receptors, and bcl-2 and bax Genes in Normal, Hyperplastic and Carcinomatous Human Prostates: Immunohistochemical Comparative Analysis , 2000, Growth factors.

[227]  A. Cuddihy,et al.  The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α , 1999, Oncogene.

[228]  E. Gold,et al.  The macrophage--a cell for all seasons. , 1999, Trends in cell biology.

[229]  M. Vidal,et al.  Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. , 1998, Genes & development.

[230]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[231]  J. Tschopp,et al.  Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. , 1998, Immunity.

[232]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[233]  M. Clerici,et al.  Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. , 1998, Journal of the National Cancer Institute.

[234]  M. Graham,et al.  IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones. , 1997, Journal of immunology.

[235]  F. Alt,et al.  Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. , 1997, Journal of immunology.

[236]  D. Venzon,et al.  Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. , 1997, Journal of the National Cancer Institute.

[237]  A. Beaulieu,et al.  Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. , 1996, Blood.

[238]  Sharon Lee,et al.  Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro , 1996, Inflammation.

[239]  C. Woodworth,et al.  Transforming growth factor beta 1 supports autonomous growth of human papillomavirus-immortalized cervical keratinocytes under conditions promoting squamous differentiation. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[240]  M. Mihm,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[241]  W. Leonard,et al.  Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[242]  T. Whiteside,et al.  Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. , 1995, Journal of immunology.

[243]  R. Noelle,et al.  Generalized autoimmune disease in interleukin‐2‐deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells , 1995, European journal of immunology.

[244]  S. Yonehara,et al.  Normal clonal expansion but impaired Fasmediated cell death and anergy induction in interleukin‐2‐deficient mice , 1995, European journal of immunology.

[245]  M. Armant,et al.  IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. , 1995, Immunology.

[246]  A. Monroy,et al.  Generation of memory CD4+, CD8+, CD45RO+ and CD16- lymphocytes activated with IL-2, INF-gamma, and TNF-alpha with specific cytotoxicity against autologous cervical cancer cells in a mixed leukocyte-tumour cell culture. , 1995, European cytokine network.

[247]  J. Skinner,et al.  Cytokine receptor expression by solid tumours. , 1995, Therapeutic immunology.

[248]  E Morelon,et al.  Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains , 1995, The Journal of cell biology.

[249]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[250]  P. Delvenne,et al.  Inhibition of growth of normal and human papillomavirus-transformed keratinocytes in monolayer and organotypic cultures by interferon-gamma and tumor necrosis factor-alpha. , 1995, The American journal of pathology.

[251]  O. Silvennoinen,et al.  Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. , 1994, Science.

[252]  P. Hebda,et al.  Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2 , 1994, International journal of cancer.

[253]  L. Trentin,et al.  Functional role of IL-2 receptors on tumour-infiltrating lymphocytes. , 1994, British Journal of Cancer.

[254]  M. Erdos,et al.  Heterodimerization of the IL-2 receptor β- and γ-chain cytoplasmic domains is required for signalling , 1994, Nature.

[255]  B. Nelson,et al.  Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation , 1994, Nature.

[256]  M. Yutsudo,et al.  Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. , 1994, Virology.

[257]  A. Feller,et al.  Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene , 1993, Cell.

[258]  T. Taniguchi,et al.  The interleukin-2 receptor complex and signal transduction: role of the β-chain , 1993 .

[259]  K. Matsushima,et al.  IL-2 up-regulates but IFN-gamma suppresses IL-8 expression in human monocytes. , 1993, Journal of immunology.

[260]  M. Colombo,et al.  Human melanoma cells express a functional interleukin‐2 receptor , 1993, International journal of cancer.

[261]  E. Heyderman,et al.  Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. , 1993, Gynecologic oncology.

[262]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[263]  T. Taniguchi,et al.  The IL-2 IL-2 receptor system: A current overview , 1993, Cell.

[264]  J. Johnson,et al.  Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. , 1992, Cancer research.

[265]  T. Luger,et al.  Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-alpha. , 1992, Journal of immunology.

[266]  M. Ferrer,et al.  High-affinity interleukin 2 receptor alpha and beta chains are internalized and remain associated inside the cells after interleukin 2 endocytosis. , 1992, The Journal of biological chemistry.

[267]  S. Voss,et al.  Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R , 1992, The Journal of experimental medicine.

[268]  D. Longo,et al.  IL-2 induces IL-6 production in human monocytes. , 1992, Journal of immunology.

[269]  M. Lenardo.  lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.

[270]  T. Luger,et al.  Constitutive release of IL6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: a mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cells. , 1991, Cellular immunology.

[271]  L. Owen-Schaub,et al.  The IL‐2 mediated amplification of cellular cytotoxicity , 1991, Journal of cellular biochemistry.

[272]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[273]  S. Sell,et al.  Interleukin 2 produced by activated B lymphocytes acts as an autocrine proliferation-inducing lymphokine. , 1990, Cytokine.

[274]  M. Awwad,et al.  The immune response to tumors. , 1989, Transplantation proceedings.

[275]  S. Cannistra,et al.  Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. , 1989, Journal of immunology.

[276]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[277]  A. Kumar,et al.  Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines. , 1987, Journal of immunology.

[278]  W. Leonard,et al.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.

[279]  B. Cullen,et al.  Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. , 1986, Science.

[280]  C. Riccardi,et al.  Generation of mouse natural killer (NK) cell activity: Effect of interleukin‐2 (IL‐2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells , 1986, International journal of cancer.

[281]  J. Ortaldo,et al.  Lymphokine-activated killer cells. Analysis of progenitors and effectors , 1986, The Journal of experimental medicine.

[282]  A. Harel-Bellan,et al.  Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation. , 1986, Journal of immunology.

[283]  A. Fauci,et al.  Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function , 1985, The Journal of experimental medicine.

[284]  T. Waldmann,et al.  Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells , 1984, Nature.

[285]  R. Suzuki,et al.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells. , 1983, Journal of immunology.

[286]  R. Suzuki,et al.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. , 1983, Journal of immunology.

[287]  B. Stadler,et al.  Cellular origin of interleukin 2 (IL 2) in man: evidence for stimulus-restricted IL 2 production by T4+ and T8+ T lymphocytes. , 1982, Journal of immunology.

[288]  A. Munck,et al.  T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.

[289]  C. Henney,et al.  Interleukin-2 augments natural killer cell activity , 1981, Nature.

[290]  Kendall A. Smith,et al.  Long term culture of tumour-specific cytotoxic T cells , 1977, Nature.

[291]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[292]  K. Iwahori.  Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[293]  Xingsheng Yang,et al.  Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer. , 2019, International journal of clinical and experimental pathology.

[294]  P. ten Dijke,et al.  Targeting TGF-β Signaling in Cancer. , 2017, Trends in cancer.

[295]  K. Medina.  Overview of the immune system. , 2016, Handbook of clinical neurology.

[296]  L. Turek,et al.  Interferon treatment of human keratinocytes harboring extrachromosomal, persistent HPV-16 plasmid genomes induces de novo viral integration. , 2015, Carcinogenesis.

[297]  D. Dolgova,et al.  [Cytokine status and neutrophil phenotype in the progression of cervical cancer]. , 2014, Voprosi onkologii.

[298]  F. Ginhoux,et al.  Ontogeny and functional specialization of dendritic cells in human and mouse. , 2013, Advances in immunology.

[299]  P. Duerksen-Hughes,et al.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. , 2011, Future virology.

[300]  J. Sprent,et al.  The role of interleukin-2 in memory CD8 cell differentiation. , 2010, Advances in experimental medicine and biology.

[301]  Deborah M. Brown,et al.  IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. , 2009, Cellular immunology.

[302]  P. Delvenne,et al.  Increased migration of Langerhans cells in response to HPV16 E6 and E7 oncogene silencing: role of CCL20 , 2008, Cancer Immunology, Immunotherapy.

[303]  G. Boulet,et al.  Human papillomavirus: E6 and E7 oncogenes. , 2007, The international journal of biochemistry & cell biology.

[304]  Ekaterina S Jordanova,et al.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. , 2007, Cancer research.

[305]  A. Thornton.  Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2. , 2006, Frontiers in bioscience : a journal and virtual library.

[306]  Mads Hald Andersen,et al.  Cytotoxic T cells. , 2006, The Journal of investigative dermatology.

[307]  M. Bobek,et al.  Dynamics of cervical langerhans cell counts in the course of HPV-positive CIN treatment with the use of human recombinant interferon gamma. , 2005, European journal of gynaecological oncology.

[308]  G. Mufti,et al.  IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[309]  M. Simões,et al.  Evaluation of Langerhans' cells in human papillomavirus-associated squamous intraepithelial lesions of the uterine cervix. , 2004, Clinical and experimental obstetrics & gynecology.

[310]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[311]  E. Shevach.  Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[312]  E. Androphy,et al.  Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. , 2000, Cancer research.

[313]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[314]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[315]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[316]  P. Lipponen,et al.  Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. , 1994, European journal of cancer.

[317]  M. Caligiuri,et al.  Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. , 1993, The Journal of clinical investigation.

[318]  A. Emmendoerffer,et al.  Influence of interleukin-2 on the differentiation of macrophages. , 1991, Pathobiology : journal of immunopathology, molecular and cellular biology.

[319]  W. Greene,et al.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. , 1988, The Journal of clinical investigation.

[320]  P. Vassalli,et al.  Administration of recombinant interleukin 2 to mice enhances production of hemopoietic and natural killer cells , 1986, European journal of immunology.